人红细胞-兔VX2肿瘤细胞融合疫苗的制备及其对兔VX2肿瘤复发转移的影响  

Preparation of Hunan Red Blood Cell-Rabbit VX2 Tumor Cell Fusion Vaccine and Its Efects on VX2 Tumor Recurrence and Metastasis

作　　者：刘险峰[1] 刘玉琴[1] 任乐荣[1] 苏广彦[1] 顾蓓[1] 董继红[1] 

机构地区：[1]中国医学科学院基础医学研究所中国协和医科大学基础医学院,北京市100005

出　　处：《中国肿瘤临床》2005年第9期530-532,共3页Chinese Journal of Clinical Oncology

基　　金：国家973项目基金资助(编号:2002CB513102)

摘　　要：目的:制备一种新型肿瘤疫苗,观察其抗肿瘤效应。方法:PEG法制备人红细胞-兔VX2细胞融合疫苗,MTT法检测疫苗体外刺激兔单核细胞增殖的作用,观察疫苗治疗对兔VX2肿瘤复发转移的影响。结果:融合疫苗体外显著刺激单核细胞增殖,后者能特异性杀伤VX2靶细胞,疫苗治疗能显著降低VX2肿瘤的复发转移率。结论:人红细胞-兔VX2细胞融合疫苗体内外均可诱导特异性抗肿瘤免疫效应,该疫苗为研究人肿瘤细胞融合疫苗提供了支持。Objective: To prepare a new tumor vaccine and observe its anti-tumor effects. Methods: The vaccine was prepared by fusion of human red blood cells and rabbit VX2 tumor cells using PEG. MTT tests were used to measure its ability to activate cytotoxic lymphocytes (CTL) in vitro. Its in vivo effect on tumor recurrence and metastasis was also evaluated using animal model. Results: The vaccine had a remarkable effect on the proliferation of peripheral blood mononuclear cells. The mononuclear cells after priming exhibited an obvious and specific cytotoxicity towards VX2 cells in vitro. In vivo, the vaccine could remarkably reduce the rate of VX2 tumor recurrence and metastasis. Conclusion: The vaccine could induce specific anti-tumor effects both in vitro and in vivo. Our results provide useful data for further study on human tumor fusion vaccine.

关 键 词：红细胞 VX2 兔 细胞融合 肿瘤疫苗 复发 转移 

分 类 号：R730.3[医药卫生—肿瘤] R730.51[医药卫生—临床医学]